undamentalytics Newsletter
Sign in

Iradimed Corp income statement

In fiscal 2025, Iradimed Corp reported revenue of $83.8m, up 14.4% on the year before, operating income of $26.1m (a 31.2% margin) and net income of $22.5m, or $1.75 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1116323223303932425366738489
Cost of revenue33666798101215171922
Gross profit812262618233024324150566467
Research and development11212212223333
Selling and marketing235567910111312161718
General and administrative2589991012101115161818
Operating income331211169−1101620222629
Income before tax331211169−1101622242831
Income tax11441−0−1−2135567
Net income22870610191317192224
Diluted EPS$0.22$0.20$0.60$0.60$0.04$0.52$0.78$0.11$0.74$1.02$1.35$1.50$1.75$1.86
Diluted shares (average)9m10m13m12m12m12m12m12m13m13m13m13m13m13m
EBITDA33121237101111621232730

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IRMD vs LUNGDCTH vs IRMDIRMD vs SGHT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Iradimed Corp's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iradimed Corp.